Standout Papers

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial 2021 2026 2022 2024238
  1. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021)
    Stephen A. Harrison, Peter Ruane et al. Nature Medicine
  2. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023)
    Stephen A. Harrison, Juan P. Frías et al. ˜The œLancet. Gastroenterology & hepatology
  3. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025)
    Mazen Noureddin, Mary E. Rinella et al. New England Journal of Medicine

Immediate Impact

2 from Science/Nature 59 standout
Sub-graph 1 of 18

Citing Papers

Metabolic dysfunction-associated steatotic liver disease in adults
2025 Standout
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
7 intermediate papers

Works of Kitty Yale being referenced

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2023 Standout
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Kitty Yale 1183 832 593 20 1.8k
Kirk D. Miller 1270 1238 488 33 2.7k
Cassy Workman 1171 1239 352 29 2.6k
Xuelian Wei 1602 1020 251 31 2.0k
Julie Borland 1232 740 337 51 1.9k
Jussi Sutinen 746 606 492 47 1.7k
Michael J. Ross 946 496 360 29 1.8k
Joaquin Valdes 1090 875 440 30 2.5k
Corey Moore 1203 1384 418 18 2.8k
Simon Vanveggel 1445 1122 300 40 1.8k
Hans-Jürgen Stellbrink 1390 1093 294 13 1.8k

All Works

Loading papers...

Rankless by CCL
2026